Get the Stockscreener App
15.51
2.44%
0.3198
Seres Therapeutics Inc stock is traded at $15.51, with a volume of 35,354.
It is up +2.44% in the last 24 hours and down -6.60% over the past month.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
See More
Previous Close:
$15.19
Open:
$15.01
24h Volume:
35,354
Relative Volume:
0.22
Market Cap:
$140.67M
Revenue:
$123.24M
Net Income/Loss:
$136.00K
P/E Ratio:
-775.49
EPS:
-0.02
Net Cash Flow:
$-148.99M
1W Performance:
+7.76%
1M Performance:
-6.60%
6M Performance:
+31.09%
1Y Performance:
-14.18%
1-Day Range:
$15.01
$16.03
1-Week Range:
$14.50
$16.03
52-Week Range:
$6.53
$29.98
Seres Therapeutics Inc Stock (MCRB) Company Profile
Name
Seres Therapeutics Inc
Sector
Industry
Phone
617 945 9626
Address
200 SIDNEY STREET, CAMBRIDGE, MA
Compare MCRB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
15.55 | 137.42M | 123.24M | 136.00K | -148.99M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.21 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.83 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
405.25 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
802.32 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.76 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-08-25 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-24-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Apr-21-23 | Initiated | JP Morgan | Neutral |
| Jul-23-21 | Downgrade | Goldman | Neutral → Sell |
| May-18-21 | Resumed | Goldman | Neutral |
| Mar-05-21 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Sep-18-20 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-11-20 | Upgrade | Jefferies | Hold → Buy |
| Apr-30-19 | Initiated | Jefferies | Hold |
| Oct-22-18 | Initiated | Chardan Capital Markets | Buy |
| Oct-13-17 | Initiated | Oppenheimer | Outperform |
| Aug-04-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-01-17 | Reiterated | FBR & Co. | Outperform |
| Aug-12-16 | Reiterated | FBR Capital | Outperform |
| Aug-01-16 | Downgrade | BofA/Merrill | Buy → Neutral |
| Aug-01-16 | Reiterated | H.C. Wainwright | Buy |
| Jul-29-16 | Resumed | H.C. Wainwright | Buy |
| Mar-30-16 | Initiated | FBR Capital | Outperform |
| Mar-03-16 | Initiated | Guggenheim | Buy |
| Jan-25-16 | Initiated | H.C. Wainwright | Buy |
| Oct-22-15 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-22-15 | Initiated | Canaccord Genuity | Buy |
| Jul-21-15 | Initiated | Goldman | Neutral |
| Jul-21-15 | Initiated | Leerink Partners | Outperform |
View All
Seres Therapeutics Inc Stock (MCRB) Latest News
Seres Therapeutics publishes new insights on VOWST mechanism By Investing.com - Investing.com India
Why Seres Therapeutics Inc. stock is rated strong buyInterest Rate Changes & Minimal Risk High Reward - bollywoodhelpline.com
Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 50-Day Moving AverageHere's Why - MarketBeat
3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround - The Globe and Mail
Why Seres Therapeutics Inc. stock is in analyst buy zoneConsumer Goods Stocks & Superior Trading Strategies - bollywoodhelpline.com
Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below 50 Day Moving AverageShould You Sell? - MarketBeat
How Seres Therapeutics Inc. stock responds to policy changesGlobal Markets & Verified Entry Point Detection - Улправда
The Great Biotech Re-Shoring: Seres Therapeutics and the New Commodity-Driven Era - FinancialContent
Will Seres Therapeutics Inc. stock deliver better than expected guidanceEarnings Growth Report & Safe Entry Point Identification - DonanımHaber
Can Seres Therapeutics Inc. (1S90) stock stage a strong rebound this quarterMarket Volume Report & Fast Gain Swing Alerts - DonanımHaber
Why analysts remain bullish on Seres Therapeutics Inc. stockRate Cut & Daily Profit Focused Stock Screening - DonanımHaber
Is Seres Therapeutics Inc. stock affected by interest rate hikesCPI Data & Weekly Return Optimization Alerts - Улправда
Will Seres Therapeutics Inc. stock gain from government policiesJuly 2025 Market Mood & Weekly Top Stock Performers List - Улправда
Seres Therapeutics Cuts Costs to Extend Cash Runway - MSN
Head-To-Head Contrast: Castle Biosciences (NASDAQ:CSTL) versus Seres Therapeutics (NASDAQ:MCRB) - Defense World
North America Human Microbiome Market - MarketsandMarkets
Guidance Update: How Seres Therapeutics Inc 1S90 stock compares with market leaders2025 Biggest Moves & Long-Term Growth Stock Strategies - moha.gov.vn
Published on: 2025-12-13 20:57:20 - moha.gov.vn
Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Above 50 Day Moving AverageHere's What Happened - MarketBeat
Seres Therapeutics (MCRB) price target increased by 31.25% to 21.42 - MSN
Seres Therapeutics, Inc. (MCRB) 5.04% in After-hours: What’s Driving the Move? - Stocks Telegraph
Seres Therapeutics Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Seres Therapeutics (NASDAQ:MCRB) Stock Passes Below 50 Day Moving Average – Here’s What Happened - Defense World
Seres Therapeutics (MCRB) Price Target Increased by 31.25% to 21.42 - Nasdaq
What risks investors should watch in Seres Therapeutics Inc. stockQuarterly Growth Report & Accurate Intraday Trading Signals - Newser
Seres Therapeutics (NASDAQ:MCRB) Stock Passes Below 50 Day Moving AverageHere's What Happened - MarketBeat
Will Seres Therapeutics Inc. (1S90) stock outperform foreign stocksWeekly Risk Summary & Real-Time Chart Pattern Alerts - Newser
Will Seres Therapeutics Inc. (1S90) stock beat value stocks2025 Year in Review & Verified Chart Pattern Signals - Newser
What market sentiment indicators show for Seres Therapeutics Inc. (1S90) stock2025 Institutional Moves & Free Daily Entry Point Trade Alerts - Newser
Is Seres Therapeutics Inc. stock dividend yield sustainablePortfolio Update Report & Growth Oriented Trade Recommendations - Newser
Is Seres Therapeutics Inc. stock positioned for long term growth2025 Support & Resistance & Growth Focused Stock Pick Reports - Newser
Seres Therapeutics (MCRB) Stock Analysis Report | Financials & Insights - Benzinga
Volatility Watch: Why Seres Therapeutics Inc. stock is rated strong buyJuly 2025 Review & High Accuracy Trade Alerts - moha.gov.vn
Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Below Fifty Day Moving AverageShould You Sell? - MarketBeat
A look into Seres Therapeutics Inc (MCRB)’s deeper side - Setenews
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference - The Manila Times
Seres Therapeutics (Nasdaq: MCRB) to join Piper Sandler 37th Annual Healthcare Conference - Stock Titan
Seres Therapeutics Inc Stock Analysis and ForecastHead and Shoulders Patterns & Big Gains Low Cost - earlytimes.in
What analysts say about Seres Therapeutics Inc stockMACD Histogram Signals & Budget Friendly Capital Growth - earlytimes.in
Should You Watch Rane Engine Valve Limited for Sector Rotation UpsideWeekly Market Snapshot & Free Stock Market Mentorship Programs - earlytimes.in
Can Poonawalla Fincorp Limited Deliver Consistent Free Cash FlowsMarket Depth Overview & Swing Trade Smarter With Data Insights - earlytimes.in
Seres Therapeutics, Inc. (MCRB) -17.5% in Normal Trading: Shares Dip Amid Recent Insider Sales - Stocks Telegraph
How reliable is Seres Therapeutics Inc. (1S90) stock dividend growth2025 Support & Resistance & Safe Swing Trade Setups - newser.com
Will Seres Therapeutics Inc. (1S90) stock extend growth storyEarnings Trend Report & Daily Market Momentum Tracking - newser.com
Is Seres Therapeutics Inc. stock a top pick in earnings season - newser.com
12 Health Care Stocks Moving In Thursday's Intraday SessionBioRestorative Therapies (NASDAQ:BRTX), (ENTO) - Benzinga
Seres Therapeutics Inc Stock (MCRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.45%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):